8-K: Hydrofarm Announces Fourth Quarter and Full Year 2024 Results, Expects Continued Challenges in 2025

Hydrofarm Holdings Group reported a decrease in net sales for both the fourth quarter and full year 2024, with expectations of continued challenges into 2025 despite cost-saving measures and strategic shifts.

Summary

• Hydrofarm's net sales decreased in Q4 2024 to $37.3 million from $47.2 million in the prior year.
• The decrease was primarily due to a decline in volume/mix of products sold related to oversupply in the cannabis industry, and a decrease in price.
• Gross Profit decreased to $1.8 million, or 4.9% of net sales, compared to $8.4 million, or 17.9% of net sales, in the prior year period.
• Net loss increased to $17.5 million, or $(3.80) per diluted share, compared to a net loss of $15.2 million, or $(3.33) per diluted share, in the prior year period.
• For the full year 2024, net sales decreased to $190.3 million compared to $226.6 million in the prior year.
• Net loss for the full year increased to $66.7 million compared to $64.8 million in the prior year.
• The company expects net sales to decrease by 10-20% in fiscal year 2025.
• Adjusted EBITDA and Free Cash Flow are expected to be negative but improved from 2024.
• As of December 31, 2024, the Company had $26.1 million in cash and approximately $13.0 million of available borrowing capacity on its Revolving Credit Facility.

Sentiment

Score: 4

Explanation: The sentiment is negative due to decreased sales, increased net losses, and a negative outlook for 2025. However, cost-saving measures and strategic shifts provide a glimmer of hope.

Positives

• SG&A expense and Adjusted SG&A expense decreased by (14.7)% and (9.8)%, respectively in Q4.
• SG&A expense and Adjusted SG&A expense decreased by (16.6)% and (16.9)%, respectively for the full year.
• Cash generated from operating activities and Free Cash Flow were $2.7 million and $2.4 million, respectively in Q4.
• The company has reduced its manufacturing footprint by nearly 60% since early 2023.
• The company's strategic focus on proprietary brands has successfully increased its sales mix of higher-margin proprietary brands from approximately 35% in 2020 to 56% in 2024.

Negatives

• Net sales decreased to $37.3 million compared to $47.2 million in Q4.
• Gross Profit Margin decreased to 4.9% of net sales compared to 17.9% in Q4.
• Net loss increased to $17.5 million compared to $15.2 million in Q4.
• Adjusted EBITDA of $(7.3) million compared to $(0.6) million in Q4.
• Net sales decreased to $190.3 million compared to $226.6 million for the full year.
• Net loss increased to $66.7 million compared to $64.8 million for the full year.
• Adjusted EBITDA of $(5.2) million compared to $0.3 million for the full year.
• Cash used in operating activities and Free Cash Flow were $(0.3) million and $(3.2) million, respectively for the full year.
• The company expects net sales to decrease by 10-20% in fiscal year 2025.
• Adjusted EBITDA and Free Cash Flow are expected to be negative in 2025.

Risks

• The market is adversely impacted by conditions of the agricultural and cannabis industries, including oversupply and decreasing prices.
• Worsening industry conditions could force additional impairment charges and/or inventory and accounts receivable reserves, potentially leading to liquidity challenges.
• The Revolving Credit Facility and future debt facilities may limit the operation of the business, including restricting the ability to sell products directly to the cannabis industry.
• The company's current stock prices are at depressed levels and any equity financing would be dilutive.
• Interruptions in the supply chain could adversely impact expected sales growth and operations.
• Increased prices and inflation could adversely impact the company's performance and financial results.
• The company may be unable to meet the continued listing standards of Nasdaq.
• The company's restructuring activities may increase expenses and cash expenditures, and may not have the intended cost saving effects.

Future Outlook

The company expects net sales to decrease by 10-20% in fiscal year 2025, with improved but still negative Adjusted EBITDA and Free Cash Flow. The outlook is predicated on improved gross profit margin, reduced SG&A expense, further reduction in inventory and net working capital, and capital expenditures of less than $2 million.

Management Comments

• In 2024, we delivered over $9 million of Adjusted SG&A expense savings, demonstrating our commitment to continued cost management to counter persistent challenging industry conditions.
• While fourth quarter industry headwinds affected our Adjusted EBITDA and Free Cash Flow performance, we successfully maintained annual sales to the mid-point of our full-year outlook.
• Our strategic focus on proprietary brands has successfully increased our sales mix of higher-margin proprietary brands from approximately 35% in 2020 to 56% in 2024.
• We've also reduced our manufacturing footprint by nearly 60% since early 2023 while maintaining excellent product quality.
• Looking ahead to 2025, we have a clear roadmap focused on reinvigorating our proprietary brand sales mix, optimizing our distribution network, and implementing additional cost-saving measures.
• We're encouraged by our e-commerce growth and revenue diversification efforts through geographic expansion and non-cannabis sales.
• We remain confident in our ability to execute on initiatives within our control and enhance long-term shareholder value.

Industry Context

The announcement reflects the ongoing challenges in the hydroponics industry, particularly related to oversupply and decreasing prices in the cannabis market. Hydrofarm is attempting to navigate these headwinds through cost management, strategic focus on proprietary brands, and diversification efforts.

Comparison to Industry Standards

• It is difficult to compare Hydrofarm's results directly to industry standards without specific competitor data.
• However, the company's focus on cost reduction and proprietary brands aligns with common strategies employed by companies in competitive industries facing market headwinds.
• The decline in sales and profitability reflects the broader challenges in the cannabis and controlled environment agriculture sectors, where oversupply and price pressures are prevalent.
• Companies like Scotts Miracle-Gro, while operating in a broader market, have also faced challenges related to the cannabis industry's volatility, indicating a sector-wide trend.

Stakeholder Impact

• Shareholders will likely be concerned about the decreased sales and increased net losses.
• Employees may be affected by continued cost-saving measures and potential restructuring.
• Customers may see changes in product offerings as the company focuses on proprietary brands.
• Suppliers may be impacted by the company's efforts to optimize its distribution network and reduce inventory levels.
• Creditors will be monitoring the company's ability to meet its debt obligations.

Next Steps

• Reinvigorate proprietary brand sales mix.
• Optimize distribution network.
• Implement additional cost-saving measures.
• Continue e-commerce growth and revenue diversification efforts through geographic expansion and non-cannabis sales.

Key Dates